Urinary incontinence, the involuntary loss of urine, is a common condition that affects approximately 50% of adult women. This condition increases with age, affecting 10% to 20% of all women and up to 77% of elderly women residing in nursing homes.
The aims of this study are to describe the postoperative incidence of de novo stress urinary incontinence (SUI) in women who underwent anterior vaginal compartment prolapse repair using synthetic polypropylene mesh and to identify risk factors for this outcome.
Prostatic abscesses are usually diagnosed in the setting of bacterial prostatitis. Rarely, they reveal or complicate granulomatous prostatitis. A 55-year-old man was admitted for acute urinary retention.
To evaluate the feasibility, efficacy, and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with treatment-resistant chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Benign prostatic hyperplasia (BPH) is the most common non-cancerous disease of the prostate and leads to lower urinary tract symptoms in middle-aged and elderly males. Fire needle therapy could improve the lower urinary tract symptoms associated with mild-moderate BPH in clinical practice.
Benign prostatic hyperplasia (BPH) is a common disease that can cause uncomfortable lower urinary tract symptoms. The occurrence of symptomatic BPH develops after the age of 40 years and increases gradually with age to reach more than 50% at the age of 60 years and severely disturbs the quality of life of the patients.
(UroToday.com) Woonyoung Choi, PhD, from the Johns Hopkins Greenberg Bladder Cancer Institute, presented on the association of molecular subtypes and Bacillus Calmette-Guerin (BCG) responses. She used the consensus subtype classification (CSC) and found no association between responders/no responders using the CSC.
(UroToday.com) Max Kates, MD, Johns Hopkins Greenberg Bladder Cancer Institute, presented mechanisms of bacillus calmette-guerin (BCG) in bladder cancer. T cell expansion is a driving force in immune cell recruitment. The immune checkpoint and BCG response has showed PDL1 expression is relatively high among patients with carcinoma in situ (CIS). Colonization of PDL1 and CD8 among BCG […]
(UroToday.com) Colin Dinney, MD, of the MD Anderson Cancer Center, discussed Nadofaragene firadenovec. He reported the initial results of 30% complete response (CR) which prompted a phase III trial for bacillus Calmette-Guerin (BCG) unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). A total of 157 patients were evaluated for safety with 151 patients for efficacy. At 3mo 53% […]
(UroToday.com) Karen Saches, Bladder Cancer Advocacy Network (BCAN) patient advocate, shared the patient perspective in the management of bacillus calmette-guerin (BCG) unresponsive high-risk non-muscle invasive bladder cancer (NMIBC).
